To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
-
Total Parkin Antibody*
Monoclonal mouse antibody directed against human Parkin. Suitable for immunohistochemistry applications, and evidence suggests this antibody may be binding to a conformational epitope.
-
Total Parkin Antibody*
Monoclonal mouse antibody directed against human Parkin. Suitable for immunoblot and immunohistochemistry experiments.
-
p62 pT138 Phosphospecific Antibody
Rabbit monoclonal phosphospecific antibody directed against Threonine 138 of the p62 protein. Suitable for immunoblotting applications.
-
RILPL1 Antibody
Rabbit monoclonal antibody directed against total rodent/human RILPL1 protein. Suitable for immunoblot, immunoprecipitation, and immunocytochemistry experiments.
-
PINK1 pS228 Phosphospecific Antibody
Rabbit monoclonal phosphospecific antibody directed against Serine 228 of PINK1.
Expected Availability: Early 2025
-
PINK1 pT257 Phosphospecific Antibody
Rabbit monoclonal phosphospecific antibody directed against Threonine 257 of human PINK1. Suitable for immunoblot applications.
-
Rab 7A pS72 Phosphospecific Antibody
Rabbit monoclonal phosphospecific antibody directed against Serine 72 of the human Rab7A protein. Suitable for immunoblot and immunohistochemical experiments.
-
PPMI iPSCs
Induced pluripotent stem cell (iPSC) lines are available through the PPMI repository. The repository includes lines from control, idiopathic PD, genetic PD (LRRK2, GBA, SNCA), genetic unaffected carriers (LRRK2, LRRK2/GBA, GBA, SNCA), and prodromal patients. Gene-revertant controls are available for select lines. An inventory of available lines can be found here: https://zenodo.org/records/10607589
Have questions or need additional information?
Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic